

1 TITLE

2 Of masks and methylene blue - the use of methylene blue photochemical treatment to decontaminate
3 surgical masks contaminated with a tenacious small non-enveloped norovirus

4

5 RUNNING TITLE

6 MB treatment of norovirus-contaminated PPE

7

8 AUTHORS

9 Constance Wielick^{a,*}, Allyson Fries^{a,*}, Lorène Dams^a, Ravo M. Razafimahefa^a, Belinda Heyne^b, Brian
10 H. Harcourt^c, Thomas S. Lendvay^d, Jean François Willaert^e, Simon de Jaeger^e, Eric Haubruge^e,
11 Etienne Thiry^{a,#}, Louisa F. Ludwig-Begall^a

12

13 AUTHOR AFFILIATIONS

14 ^a Veterinary Virology and Animal Viral Diseases, Department of Infectious and Parasitic Diseases,
15 FARAH Research Centre, Faculty of Veterinary Medicine, Liège University, Liège, Belgium

16 ^b Department of Chemistry, University of Calgary, 2500 University Drive Northwest, Calgary, T2N
17 1N4, Alberta, Canada

18 ^c Viral Special Pathogens Branch, Division of High Consequence Pathogens and Pathology, Centers
19 for Disease Control and Prevention, Atlanta, USA

20 ^d Department of Urology, University of Washington School of Medicine, Seattle Children's Hospital,
21 Seattle, Washington, USA

22 ^e TERRA Research Centre, Gembloux Agro-Bio Tech, University of Liège, Gembloux, Belgium

23

24 *These authors contributed equally to this work.

Non-standard abbreviations:

FFR: filtering facepiece respirator

SM: surgical mask

MNV: murine norovirus

SARS-CoV-2: severe acute respiratory syndrome coronavirus 2

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 #Corresponding author: email: etienne.thiry@uliege.be; phone: 0032 (0) 4 366 42 51; address:
26 Veterinary Virology and Animal Viral Diseases, DMI, FMV, FARAH, ULiège, B43b, Quartier Vallée
27 2, Avenue de Cureghem, 10, B-4000 Liège, Belgium; Orcid ID: 0000-0002-9585-7933
28
29 WORD COUNT: 3884 (Introduction, Materials and Methods, Results and Discussion)

Non-standard abbreviations:

FFR: filtering facepiece respirator

SM: surgical mask

MNV: murine norovirus

SARS-CoV-2: severe acute respiratory syndrome coronavirus 2

30 ABSTRACT

31 Background

32 In the context of the SARS-CoV-2 pandemic, reuse of personal protective equipment, specifically that
33 of medical face coverings, has been recommended. The reuse of these typically single-use only items
34 necessitates procedures to inactivate contaminating human respiratory and gastrointestinal pathogens.
35 We previously demonstrated decontamination of surgical masks and respirators contaminated with
36 infectious SARS-CoV-2 and various animal coronaviruses via low concentration- and short exposure
37 methylene blue photochemical treatment (10 μ M methylene blue, 30 minutes of 12,500-lux red light
38 or 50,000 lux white light exposure).

39 Methods

40 Here, we describe the adaptation of this protocol to the decontamination of a more resistant, non-
41 enveloped gastrointestinal virus and demonstrate efficient photodynamic inactivation of murine
42 norovirus, a human norovirus surrogate.

43 Results

44 Methylene blue photochemical treatment (100 μ M methylene blue, 30 minutes of 12,500-lux red light
45 exposure) of murine norovirus-contaminated masks reduced infectious viral titres by over four orders
46 of magnitude on surgical mask surfaces.

47 Discussion and Conclusions

48 Inactivation of a norovirus, the most difficult to inactivate of the respiratory and gastrointestinal
49 human viruses, can predict the inactivation of any less resistant viral mask contaminant. The protocol
50 developed here thus solidifies the position of methylene blue photochemical decontamination as an
51 important tool in the package of practical pandemic preparedness.

52

53

54 KEYWORDS

55 Methylene blue photochemical treatment; singlet oxygen; decontamination; surgical mask;
56 coronavirus; norovirus

57

58 INTRODUCTION

59

60 In the context of the ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
61 pandemic, the supply of personal protective equipment (PPE) remains under strain. In a turn from the
62 prevailing culture of throwaway living towards a sustainable circular economy within the healthcare
63 industry [1,2], re-use of typically single-use only face coverings such as surgical face masks (SMs)
64 and filtering facepiece respirators (FFRs) has been recommended [3,4]. Prior decontamination is
65 paramount to safe PPE re-use and must guarantee the complete inactivation of SARS-CoV-2 as well
66 as that of other contaminating respiratory or gastrointestinal human pathogens [5]. This is relevant in
67 current circumstances (contamination with pathogens other than SARS-CoV-2 might easily occur,
68 particularly in the context of widespread mask use and inexpert donning and doffing), but also plays a
69 significant role in positioning the world for future pandemics [6].

70

71 Human respiratory pathogens include other enveloped corona-, pneumo-, metapneumo-, paramyxo-,
72 and orthomyxoviruses as well as non-enveloped coxsackie- and rhinoviruses; gastrointestinal
73 pathogens include boca-, astro-, picorna-, rota- and noroviruses (all non-enveloped) [7]. While
74 enveloped viruses, surrounded by an outer lipid layer, are susceptible to inactivating treatments, non-
75 enveloped viruses are known to be significantly more resistant. Amongst them, the small, non-
76 enveloped human norovirus (genus *Norovirus*, family *Caliciviridae*), recognised as the major global
77 cause of viral gastroenteritis [8], is notorious for its tenacity in the face of decontamination and as such
78 may be considered the gold standard for validating viral inactivation [9,10]. The genetically and
79 structurally similar murine norovirus (MNV), which replicates efficiently *in vitro*, has been identified
80 as an appropriate surrogate for modelling human norovirus inactivation [11].

81

82 We previously demonstrated efficient inactivation of both a SARS-CoV-2 surrogate and an infectious
83 animal norovirus via hydrogen peroxide-, ultraviolet germicidal irradiation-, and dry heat
84 decontamination [12–14]. Particularly, the former two technologies, while easily deployable and
85 extremely useful in high-resource settings, are not equitable as they remain less available in low-

86 resource settings; accessible alternative decontamination methods are thus necessary to mitigate PPE
87 shortages in restricted surroundings.

88

89 To address this issue, the Development and Methods for N95 Respirators and Mask Decontamination
90 (DeMaND) study recently established a low-cost methylene blue (MB) photochemical treatment for
91 the efficient decontamination of SMs and FFRs contaminated with infectious SARS-CoV-2 or
92 surrogate animal coronaviruses [15]. Photosensitive MB dye, FDA-approved as an oxidation-reduction
93 agent for the treatment of acquired methaemoglobinemia, has a long-standing history of use in
94 pathogen inactivation both in the context of plasma treatment [16–18] and maxillary sinusitis therapy
95 [19]. For its application to photochemical PPE decontamination, contaminated materials were coated
96 with MB and subsequently exposed to a visible light source triggering the generation of virucidal
97 singlet oxygen. A 10 μM MB concentration and a 30-minute exposure to 12,500 lux (10.474 W/m^2) of
98 red light or 50,000 lux (39 W/m^2) of white light reduced titres of SARS-CoV-2 and two surrogate
99 viruses by more than three orders of magnitude on all tested materials [15].

100

101 In the present investigation into decontamination of virus-inoculated SMs, we demonstrate
102 inactivation of a highly resistant, small non-enveloped norovirus via MB photochemical treatment.
103 Decontamination via a protocol adapted from the DeMaND study and involving the spray-coating of
104 SMs with a 100 μM MB solution followed by 30 minutes of 12,500-lux red light exposure, robustly
105 reduced infectious norovirus titres by over four orders of magnitude on SM coupons, this in excess of
106 the three orders of magnitude reduction outlined in the current FDA policy regarding face masks and
107 respirators [5]. This study serves to future-proof MB photochemical treatment since inactivation of a
108 norovirus, the most resistant of the respiratory and gastrointestinal human viruses, can predict the
109 inactivation of any less resistant viral mask contaminant. The protocol developed here thus solidifies
110 the position of MB decontamination as an important tool in the package of practical pandemic
111 preparedness.

112

113 **METHODS**

114

115 **Viruses and cells**

116 Murine macrophage cell line RAW264.7 (ATCC TIB-71) was maintained in Dulbecco's modified
117 Eagle's medium (Invitrogen) complemented with 10% heat inactivated foetal calf serum (FCS)
118 (BioWhittaker), 2% of an association of penicillin (5000 SI units/mL) and streptomycin (5 mg/mL)
119 (PS, Invitrogen) and 1% 1 M HEPES buffer (pH 7.6) (Invitrogen) (DMEMc) at 37 °C with 5% CO₂.
120 Stocks of MNV isolate MNV-1.CW1 were produced by infection of RAW264.7 cells at a multiplicity
121 of infection of 0.05. Two days post-infection, cells and supernatant were harvested and clarified by
122 centrifugation for 20 minutes at 1000 x g after three freeze/thaw cycles (- 80°C/37°C). Titres were
123 determined via TCID₅₀ method; RAW 264.7 cells were seeded in 96-well plates, infected with ten-fold
124 serial dilutions of MNV, incubated for three days at 37 °C with 5% CO₂, and finally stained with 0.2%
125 crystal violet for 30 minutes. Titres, expressed as TCID₅₀/mL, were calculated according to the Reed
126 and Muench transformation [22]. A virus stock with a titre of 7.06 log₁₀ TCID₅₀/mL was used in
127 subsequent steps.

128

129 The continuous swine testicle (ST) cell-line, grown from testicular foetal swine tissues as described by
130 McClurkin and Norman (1966) [20], was maintained in MEM (GIBCO), supplemented with 5% foetal
131 calf serum (FCS) (Sigma), 1% sodium pyruvate 100x (GIBCO), and antibiotics (100U/mL penicillin,
132 0.1mg/mL streptomycin and 0.05 mg/mL gentamycin). Porcine respiratory coronavirus (PRCV) strain
133 91V44 [21] was passaged three times on confluent ST monolayers. Titres were determined via the
134 tissue culture infective dose (TCID₅₀) method; ST cells were seeded in 96-well plates and infected
135 with ten-fold serial dilutions of PRCV and incubated for four days at 37 °C with 5% CO₂. Four days
136 after inoculation, monolayers were analysed for the presence of cytopathic effect by light microscopy.
137 Titres, expressed as TCID₅₀/mL, were calculated according to the Reed and Muench transformation
138 [22]. A PRCV stock with a titre of 7.80 log₁₀ TCID₅₀/mL was used in subsequent steps.

139

140 **Surgical masks**

141 Type IIR-Class I three-layer medical masks manufactured by Zarena AD, Bulgaria (LOT 0420; REF
142 FMN99) were utilised in all assays. All masks, verified to be from the same manufacturing lot, were
143 supplied by the Department of the Hospital Pharmacy, University Hospital Centre of Liege (Sart-
144 Tilman).

145

146 **Light box**

147 The light box designed by the Terra Research Centre and previously used for MB activation and
148 PRCV decontamination in the context of the DeMaND study [15] contains six 180 W horticultural
149 LED lamps (Roleadro Culture Indoor IP65 LED Horticultural T5 Grow), which together emit 12,500
150 LUX (or 10.474 W/m²) at 660 nm wavelength (luminescence verified using a light metre (DeltaOHM,
151 Model HD2102.2)). The box interior is cooled by a ventilator equilibrating temperatures within the
152 box (thus eliminating possible temperature effects on viral titres). Exposure to the red light within the
153 light box (LB) is henceforth referred to as “LB exposure”. The design specifications of the light box
154 have been made available in open source.

155

156 **Validation of previously established methylene blue photochemical decontamination using a** 157 **porcine coronavirus and evaluation of its efficacy in inactivating a murine norovirus**

158 To validate previously published MB photochemical treatment conditions (10 µM MB and 30-minutes
159 of LB exposure) and to set a “baseline” for further assays involving MNV inocula, the previously
160 established DeMaND protocol was investigated on SMs experimentally inoculated with PRCV. The
161 same protocol was then tested for decontamination of MNV-inoculated SMs. The general workflow
162 followed previously described protocols for PRCV or MNV [12–14] inoculation, MB photochemical
163 treatment [15], and virus elution from SMs [12–14] and is also described in more detail below.
164 Briefly, following injection of 100 µl undiluted PRCV or MNV suspension (7.80 and 7.06 log₁₀
165 TCID₅₀/mL, respectively; verified via back-titration) under the first outer layer of designated SM
166 coupons, inoculated SMs were comprehensively sprayed with 7 – 8 mL of a 10 µM MB solution

167 (Sigma-Aldrich (M9140); solution prepared in deionised water; total dose of 0.024 mg MB per SM),
168 allowed to dry, and were then either kept in the dark or submitted to LB exposure for a duration of 30
169 minutes. Upon completion of the decontamination protocol, PRCV or MNV was eluted from the
170 excised coupons and titres of recovered virus were determined via TCID₅₀ assay in ST (PRCV) or
171 RAW264.6 (MNV) cells. Methylene blue only controls (cytotoxicity test) and virus only controls
172 (positive control) accompanied these assays.

173

174 **Establishment of concentration- and time-dependent virucidal kinetics of methylene blue** 175 **photochemical treatment on murine norovirus**

176 **Virucidal methylene blue and light kinetics - microplate assay**

177 To establish optimal treatment conditions and determine potential combined cytotoxic effects of
178 higher concentrations of MB and light (MBL) on RAW264.7 cells, concentration- and LB exposure
179 time-dependent virucidal MBL kinetics were investigated in a set of preliminary microplate-based
180 assays. Ten-fold MB dilutions in deionised water (at final concentrations of 10 µM, 100 µM, and 1000
181 µM) in a total volume of 500 µL DMEMc (additionally supplemented with 0.1% beta-
182 mercaptoethanol) were added per well of a 48-well plate containing 10 µL MNV (7.80 log₁₀
183 TCID₅₀/mL) (technical triplicates were performed utilising separate 48-well plates). The plates were
184 then either kept in the dark (0 minute LB exposure) or were subjected to LB exposure for 30 minutes,
185 60 minutes, 90 minutes, or 120 minutes. In a second step, 100 µM and 1000 µM MB concentrations
186 were tested against high-titre MNV (8.55 log₁₀ TCID₅₀/mL) with LB exposure times of 1 hour, 2
187 hours, 3 hours, and 4 hours. Methylene blue only controls (cytotoxicity test) and virus only controls
188 (positive control) accompanied each assay. Titres of infectious MNV recovered from individual wells
189 were determined via TCID₅₀ assay. Back titrations of inoculum stocks were performed in parallel to
190 each series of decontamination experiments.

191

192 **Virucidal methylene blue kinetics - surgical mask assay**

193 To establish optimal applied treatment conditions, LB exposure time- and concentration-dependent
194 virucidal kinetics of MB were investigated on SMs experimentally inoculated with MNV.

195 *Murine norovirus inoculation onto surgical masks*

196 The workflow followed previously described protocols for SM inoculation with MNV [12,14]. Per
197 SM, 100 µl of undiluted viral suspension were injected under the first outer layer at the centre of each
198 of three square coupons (34 mm x 34 mm). The SMs were allowed to dry for 20 minutes at room
199 temperature before decontamination via MB photochemical treatment.

200 *Methylene blue photochemical treatment of surgical masks*

201 Inoculated SMs were placed horizontally and were sprayed with a total volume of 7-8 mL of either a
202 100 µM or 1000 µM MB solution (the final MB volume was determined based on six repetitive sprays
203 into a graduated cylinder). In total, each SM was sprayed four times on the outer side and twice on the
204 inner side (facing the wearer). Surgical masks were allowed to dry (absorption of the MB solution) for
205 30 minutes in a dark box and were then either kept in the dark (0-minute LB exposure) or were
206 subjected to LB exposure for 120 minutes, 180 minutes, or 240 minutes. Methylene blue only controls
207 (cytotoxicity test) and virus only controls (positive control) again accompanied each assay.

208 *Murine norovirus elution from surgical masks*

209 Upon completion of the decontamination protocol, downstream coupon excision and virus elution
210 followed previously described protocols [12,13]. Briefly, MNV was eluted from three excised coupons
211 per SM into 4 mL DMEMc via a 1-minute vortex at maximum speed (2500 rounds per minute; VWR
212 VX-2500 Multi-Tube Vortexer). Titres of infectious MNV recovered from individual coupons were
213 determined via TCID₅₀ assay. Back titrations of inoculum stocks were performed in parallel to each
214 series of decontamination experiments.

215

216 **Validation of a virucidal photochemical methylene blue treatment to decontaminate murine**
217 **norovirus – inoculated surgical masks**

218 To verify a treatment protocol wherein MNV-inoculated SMs ($7.5 \log_{10}$ TCID₅₀/mL) were sprayed
219 with 100 μ M MB and subjected to LB exposure for 30 minutes, four biological and technical repeats
220 were performed on four different days. Methylene blue only controls (cytotoxicity test) and virus only
221 controls (positive control) accompanied these assays.

222

223 **Testing shorter light box exposure (15 minutes) for photochemical methylene blue** 224 **decontamination of murine norovirus – inoculated surgical masks**

225 In an additional step, 100 μ M MB concentrations were tested against MNV-inoculated SMs (7.30
226 \log_{10} TCID₅₀/mL) in conjunction with a shorter LB exposure time of 15 minutes (biological and
227 technical triplicates). Methylene blue only controls (cytotoxicity test) and virus only controls (positive
228 control) again accompanied these assays.

229

230 **Data analysis**

231 Differences in infectious viral titres were computed and all graphs created using GraphPad Prism 7
232 (Graph-Pad Software). Statistical analyses of differences in infectious viral titres were performed
233 using GraphPad Prism 7 (Graph-Pad Software) and P-values were computed by using a two-sided
234 independent sample t-test, where ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05, and ns is P \geq 0.05.

235

236 **RESULTS**


237

238 **Methylene blue photochemical treatment of surgical masks following previously established** 239 **protocols for coronavirus inactivation reduces porcine respiratory coronavirus titres by over** 240 **five orders of magnitude but does not inactivate murine norovirus**

241 Photochemical treatment involving application of a 10 μ M MB solution and a 30-minute LB exposure
242 reduced infectious PRCV titres to below the assay detection limit of 0.8 \log_{10} TCID₅₀/mL on SM
243 coupons ($5.33 (\pm 0.25) \log_{10}$ TCID₅₀/mL reduction). Following the same treatment protocol, MNV titres

244 dropped from 5.78 (± 0.33) \log_{10} TCID₅₀/mL to 5.19 (± 0.16) \log_{10} TCID₅₀/mL, resulting in a total
245 reduction of 0.53 (± 0.34) TCID₅₀/mL (Figure 1).

246 ---



247

248 **Figure 1.** Validation of the previously established methylene blue (MB) photochemical treatment protocol using an
249 enveloped animal coronavirus (left panel) and evaluation of its efficacy in inactivating a small non-enveloped norovirus
250 (right panel). Porcine respiratory coronavirus (PRCV) - or murine norovirus (MNV) - inoculated surgical mask coupons
251 remained untreated (c+) or were treated with a 10 μ M MB solution and exposed to a 12,500-lux red light source (light box)
252 for 30 minutes (MBL). The infectivity of PRCV recovered from surgical mask coupons (n=3) was analysed in swine
253 testicular cells. The infectivity of MNV recovered from mask coupons (n=9) was analysed in RAW 264.7 cells. Values for
254 positive controls (MB-untreated, but light box-exposed) ranged between 5.80 and 6.63 \log_{10} TCID₅₀/mL (PRCV) 5.05 and
255 6.05 \log_{10} TCID₅₀/mL (MNV). The cell culture limit of detection (LOD) was 0.80 \log_{10} TCID₅₀/mL for all analyses. Means
256 \log_{10} TCID₅₀/mL and standard deviations are represented. P-values were computed by using a two-sided independent sample
257 t-test (where ****P<0.0001).


258 ---

259 **Murine norovirus inactivation in microplates via methylene blue photochemical treatment is** 260 **concentration- and time-dependent**

261 To establish optimal MNV treatment conditions, a preliminary microplate-based assay examined
262 concentration- and LB exposure time-dependent virucidal kinetics of MB photochemical treatment.
263 Again, treatment with 10 μ M MB concentrations and 30 minutes of LB exposure (treatment conditions
264 previously utilised to successfully inactivate SARS-CoV-2 and its surrogates by more than three
265 orders of magnitude [23]) reduced viral titres by less than one order of magnitude (0.73 (± 0.53) \log_{10}
266 TCID₅₀/mL). Protocols combining the same LB exposure time with 100 μ M and 1000 μ M MB
267 concentrations both reduced MNV titres by 0.93 (± 0.35) \log_{10} TCID₅₀/mL. With increasing exposure

268 times, viral titres successively dropped, reaching absolute titre reductions of 1.73 (\pm 0.53), 2.68 (\pm
269 0.35), and 2.50 (\pm 0.00) \log_{10} TCID₅₀/mL after 120 minutes (2 hours) of LB exposure in conjunction
270 with 10 μ M, 100 μ M, and 1000 μ M MB concentrations, respectively. Ten-fold increases in MB
271 concentrations coincided with higher MB cytotoxicity and correspondingly elevated assay detection
272 limits (LODs) from 0.8 to 1.8, to 2.8 \log_{10} TCID₅₀/mL (Figure 2).

273 ---



274


275 **Figure 2.** Evaluation of concentration- and time-dependent virucidal kinetics of methylene blue (MB) photochemical
276 treatment on murine norovirus (MNV) *in vitro*. The infectivity of MNV recovered from microplate wells containing medium
277 and MB at different concentrations and exposed to a 12,500-lux red light source (light box) was analysed in RAW 264.7
278 cells. The cell culture limit of detection (LOD) was 0.80, 1.8, and 2.8 \log_{10} TCID₅₀/mL for 10 μ M MB, 100 μ M MB, and
279 1000 μ M MB concentrations, respectively. All assays were performed as technical duplicates (n=2). Means \log_{10} TCID₅₀/mL
280 and standard deviations are represented. Values for positive controls (MB-untreated, but light box-exposed MNV) ranged
281 between 4.80 and 5.30 \log_{10} TCID₅₀/mL.

282 ---

283 In a second microplate-based assay, 100 μ M and 1000 μ M concentrations were tested against high-
284 titre MNV in conjunction with longer LB exposure times of 1 hour, 2 hours, 3 hours, and 4 hours.
285 Following 2 hours of LB exposure, virus titre reductions mirrored those observed in the first assay at
286 this time point (2.69 (\pm 1.66) and 2.85 (\pm 1.58) \log_{10} TCID₅₀/mL after treatment with 100 μ M and
287 1000 μ M MB solutions). Following treatment with a 100 μ M MB solution and 3 hours of LB
288 exposure, viral titres dropped by 4.80 (\pm 1.01) \log_{10} TCID₅₀/mL; treatment with 100 μ M MB and 4
289 hours of LB exposure as well as a 1000 μ M MB followed by 3 and 4 hours of LB exposure lowered

290 viral titres to below the LODs of each of the respective assays, thus yielding minimal titre reductions
291 of $3.89 (\pm 0.90)$, $3.22 (\pm 1.45)$, and $2.89 (\pm 1.40)$ \log_{10} TCID₅₀/mL, respectively (Figure 3).

292 ---



293

294 **Figure 3.** Evaluation of concentration- and longer exposure time-dependent virucidal kinetics of methylene blue (MB)
295 photochemical treatment on murine norovirus (MNV) *in vitro*. The infectivity of MNV recovered from microplate wells
296 containing medium and MB at different concentrations and exposed to a 12,500-lux red light source (light box) was analysed
297 in RAW 264.7 cells. The cell culture limit of detection (LOD) was 1.8, and 2.8 \log_{10} TCID₅₀/mL for 100 µM MB and 1000
298 µM MB concentrations, respectively. All assays were performed as biological triplicates and technical duplicates (n=6).
299 Means \log_{10} TCID₅₀/mL and standard deviations are represented. Values for positive controls (MB-untreated, but light box-
300 exposed MNV) ranged between 5.69 and 6.19 \log_{10} TCID₅₀/mL.

301 ---


302 **Murine norovirus inactivation on surgical masks via methylene blue photochemical treatment is** 303 **concentration- and time-dependent**

304 To establish optimal applied treatment conditions on the actual PPE items themselves, LB exposure
305 time- and concentration-dependent virucidal kinetics of MB were investigated on SMs experimentally
306 inoculated with MNV. 100 µM and 1000 µM methylene blue solution were applied to inoculated SMs
307 which were subsequently subjected to 2 hours, 3 hours, or 4 hours of LB exposure. Limits of
308 detections of both series of experiments were respectively lowered by one order of magnitude in these
309 assays (0.8 instead of 1.8 and 1.8 instead of 2.8 \log_{10} TCID₅₀/mL for 100 µM and 1000 µM
310 concentrations, respectively; effect attributed to a dilution of cytotoxic MB during elution), allowing
311 determination of virus titre reductions of close to or more than four orders of magnitude for 100 µM

312 concentrations at all three exposure times (3.96 (\pm 0.29), 4.10 (\pm 0.00), and 4.13 (\pm 0.00) \log_{10}
313 TCID₅₀/mL) and over three orders of magnitude for 1000 μ M concentrations (3.20 (\pm 0.00), 3.10 (\pm
314 0.00), 3.33 (\pm 0.14) \log_{10} TCID₅₀/mL) (Figure 4). At 1000 μ M concentrations, MB solutions were
315 macroscopically seen to undergo a (subjective) colour change from blue to violet (putatively indicative
316 of aggregation) and to become viscous and agglomerate on SM surfaces, thus slowing the drying
317 process.

318 ---

319



320

321 **Figure 4.** Evaluation of concentration- and time-dependent virucidal kinetics of methylene blue (MB) photochemical
322 treatment on murine norovirus (MNV) – inoculated surgical masks. The infectivity of MNV recovered from surgical mask
323 coupons treated with 100 μ M or 1000 μ M MB concentrations and subsequently exposed to a 12,500-lux red light source
324 (light box) was analysed in RAW 264.7 cells. The cell culture limits of detection (LOD) were 0.8 and 1.8 \log_{10} TCID₅₀/mL
325 for 100 μ M and 1000 μ M MB concentrations, respectively. All assays were performed as biological triplicates (n=3). Means
326 \log_{10} TCID₅₀/mL and standard deviations are represented. Values for positive controls (MB-untreated, but light box-exposed
327 MNV) ranged between 4.90 and 5.71 \log_{10} TCID₅₀/mL.


328 ---

329 **Murine norovirus-inoculated surgical masks are reliably decontaminated via photochemical**
330 **treatment involving 100 μ M methylene blue coating of masks followed by 30 minutes of 12,500-**
331 **lux red light exposure**

332 To avoid issues associated with 1000 μ M methylene blue concentrations (higher assay LOD, slow
333 drying, putatively shifted absorption spectrum), further PPE-applied assays included only the 100 μ M

334 dye concentration. Based on the high reductions of infectious MNV titres of over three orders of
335 magnitude from a 2-hour exposure onwards and in view of potentially achieving faster
336 decontamination turn-around, shorter exposure times (90 minutes, 60 minutes, 30 minutes) were tested
337 in a small preliminary assay (results not shown). Since high viral titre reductions were already
338 observed following a 30-minute exposure in this preliminary assay, the 30-minute exposure was then
339 tested and validated in four individual biological repeats (technical triplicates) (Figure 5). In addition,
340 15-minute LB exposures were assayed as biological and technical triplicates (Figure 6). While both
341 the 30-minute- and the 15-minute protocol reduced mean infectious MNV titres by more than four
342 orders of magnitude ($4.71 (\pm 0.10) \log_{10} \text{TCID}_{50}/\text{mL}$ and $4.53 (\pm 0.23) \log_{10} \text{TCID}_{50}/\text{mL}$, respectively),
343 the shorter LB exposure led to higher inter-SM (and inter-coupon) variability (Figure 6) and did not
344 consistently reduce virus titres to below the assay LOD.


345 --



346

347 **Figure 5.** Evaluation of methylene blue (MB) photochemical treatment on murine norovirus (MNV) – inoculated surgical
348 masks. The infectivity of MNV recovered from mask coupons treated with 100 μM MB and subsequently exposed to a
349 12,500-lux red light source (light box) for 30 minutes was analysed in RAW 264.7 cells. The cell culture limit of detection
350 (LOD) was $0.8 \log_{10} \text{TCID}_{50}/\text{mL}$. All assays were performed as biological quadruplicates and technical triplicates ($n=12$).
351 Means $\log_{10} \text{TCID}_{50}/\text{mL}$ and standard deviations are represented. Values for positive controls (MB-untreated, but light box-
352 exposed MNV) ranged between 5.80 and 6.05 $\text{TCID}_{50}/\text{mL}$. P-values were computed by using a two-sided independent
353 sample t-test (where **** $P < 0.0001$).

354 ---



355

356 **Figure 6.** Evaluation of methylene blue (MB) photochemical treatment on murine norovirus (MNV) – inoculated surgical
357 masks. The infectivity of MNV recovered from mask coupons treated with 100 μ M MB and subsequently exposed for 15
358 minutes to a 12,500-lux red light source (light box) was analysed in RAW 264.7 cells. The cell culture limit of detection
359 (LOD) was 0.8 \log_{10} TCID₅₀/mL. All assays were performed as biological and technical triplicates (n=9). The left panel
360 represents a summary analysis of all obtained values. The right panel shows results for individual masks (n=3) and illustrates
361 the varying decontamination efficacies of this protocol. Means \log_{10} TCID₅₀/mL and standard deviations are represented.
362 Values for positive controls (MB-untreated, but light box-exposed MNV) ranged between 5.05 and 6.55 TCID₅₀/mL. P-
363 values were computed by using a two-sided independent sample t-test (where ****P<0.0001).

364

365 DISCUSSION AND CONCLUSIONS

366 Supply issues at the beginning of the COVID-19 pandemic impressively illustrated that the world at
367 large needs to be better positioned to deal quickly with prospective, potentially unknown, disease-
368 causing agents and sanitary crises. Decontamination methods developed now, and perforce primarily
369 targeting SARS-CoV-2, should thus already be future-proofed at this time by testing them against
370 hardier pathogens. Here, we adapted an inexpensive and universally accessible photochemical
371 decontamination protocol, recently developed against SARS-CoV-2 and other coronaviruses
372 (DeMaND study) [15], to the treatment of norovirus-inoculated surgical masks.

373

374 To validate previously published MB photochemical treatment conditions [15] and to set a “baseline”
375 for further development, the DeMaND MBL protocol involving 10 μ M MB and 30-minutes of LB
376 exposure was first investigated on either PRCV- or MNV-inoculated SMs. While this treatment

377 reduced PRCV titres by over five orders of magnitude, it did not lead to significant inactivation of
378 MNV.

379

380 Ten- and hundred-fold higher MB concentrations were subsequently tested in combination with longer
381 LB exposures, first in a series of microplate-based assays and subsequently on MNV-inoculated SMs.

382 In line with previous assays reporting oxygen-dependent laser inactivation of MNV (in solution) after

383 long LB exposure times [24], inactivation of MNV proved both concentration- and time dependent in

384 both matrices. In microplates, 100 μ M MB concentrations markedly improved infectious titre

385 reductions; 1000 μ M MB solutions, however, did not further visibly enhance infectivity losses, this

386 likely attributable to a saturation effect (the assay LOD and a minimum $4.80 (\pm 1.01) \log_{10} \text{TCID}_{50}/\text{mL}$

387 titre reduction were attained with 100 μ M MB after 3 hours of LB exposure). Interestingly, MNV

388 inactivation proved to be significantly more efficacious on SMs than in microplates and titre

389 reductions of close to four orders of magnitude were already reached following 2 hours of LB

390 exposure in initial SM assays.

391

392 The differences between MNV inactivation in microplates and SMs may be attributable to two not

393 mutually exclusive effects. Thus, the LB-emitted light may not have been sufficiently powerful as to

394 penetrate a highly concentrated 100 μ M solution in deep microplate wells, whereas MB sprayed as a

395 thin surface layer onto SMs was easily accessible to photons, presenting better opportunities for

396 excitation and singlet oxygen production. Equally, since the concentration of oxygen in air is one

397 order of magnitude greater than in water [25], a thin liquid-air interface (MB spray on SMs) could

398 have positively impacted singlet oxygen production, whereas a larger-volume liquid phase (MB

399 solution in microplate wells) may have had a negative impact.

400

401 Consolidated tests demonstrated that a MBL protocol involving 100 μ M MB and a 30-minute LB

402 exposure reliably reduced infectious MNV titres by more than four orders of magnitude. Shorter LB

403 exposure led to higher inter-SM (and inter-coupon) variability and did not as consistently reduce MNV

404 titres to below the assay LOD. A protocol involving shorter LB exposure times may be achievable via

405 optimisation of MB dispersion (greater homogeneity via standardised nebuliser may improve virus
406 inactivation); meanwhile, the 30-minute LB exposure in conjunction with simple MB application via
407 spray bottle presents a low-cost and low-tech protocol and is recommended at this time for the
408 inactivation of small non-enveloped viruses. The light box utilised in this study is simply constructed
409 and uses commercially available horticultural LED lamps; further simplification of the method may be
410 achieved by eliminating the need for light boxes entirely – the possibility of leveraging solar
411 irradiation for MB activation is currently under investigation by other teams within the DeMaND
412 consortium.

413

414 The precise mode of action of MB is yet to be determined [16]; while the vastly different
415 sensitivities between PRCV and MNV may implicate the viral envelope as being one of the targets of
416 MBL treatment, varying densities of viral proteinaceous capsids as well as differences in viral genome
417 size and corresponding susceptibility to nucleic acid strand breakage (at 7.4 kb MNV is roughly four
418 times smaller than PRCV) may also play a role. Further studies are indicated to pinpoint the definitive
419 virucidal effect(s) of photochemical decontamination.

420

421 Methylene blue photochemical treatment is easily adaptable to other SM or FFR types [15]. Owing to
422 the variation in SM and FFR models (each FFR model has distinct filter materials and design
423 characteristics which may result in variable outcomes of decontamination efficacy) the CDC
424 recommends that the effectiveness of a decontamination be evaluated for specific FFRs in
425 collaboration with the manufacturer, and if needed, a third-party laboratory. This holds true for
426 inactivation of all contaminants and should ideally be performed for the norovirus-inactivating
427 conditions tested in our study.

428

429 Methylene blue concentrations necessary for norovirus inactivation (the total dose of MB per SM is
430 0.24 mg), are ten-fold higher than those needed for coronavirus decontamination. Since there is

431 considerable clinical experience to support that MB exhibits good safety [26,27] and MB
432 concentrations used here were below those administered clinically, the use of this higher dose is
433 unlikely to pose safety concerns. In addition, ultraviolet spectroscopy analyses testing the amount of
434 MB that may leach off SMs and be inhaled by a wearer during the course of a ten-hour healthcare
435 provider work shift, have shown that MB does not leach off SM (or other PPE) materials (unpublished
436 data; ongoing project with the WHO). Briefly, a panel of SMs, FFRs, and a cloth community mask
437 were subjected to a total of five 1000 μ M MB treatment cycles (1000 μ M MB solution; total volume:
438 35 – 40 mL MB applied). Treated and excised PPE coupons were then subjected to full-mask
439 equivalent airflow rates of 120 L/minute with a total airflow of 43,200 L/coupon. With a level of
440 detection of 0.004 mg/m³, no MB was observed within the spectroscopy parameters for all tested PPE
441 items.

442

443 This is the first description of stable MB photochemical decontamination of SMs contaminated with
444 an infectious norovirus. We describe successful validation of MB photochemical treatment for
445 inactivation of small non-enveloped viruses that exceeds current FDA policy recommendations [5].
446 The highly resistant MNV surrogate supplements existing data regarding photochemical
447 decontamination of SMs. It serves to future-proof this method against viral mask (and other PPE)
448 contaminants, thus solidifying the position of MBL PPE treatment both to combat PPE shortages in
449 austere or low resource environments and as an important tool in the global package of practical
450 pandemic preparedness.

451

452 ACKNOWLEDGEMENTS

453 We thank May C. Chu (Department of Epidemiology, Colorado School of Public Health, Aurora,
454 Colorado, USA) for her excellent management of the DeMaND consortium and her valuable help in
455 setting up the DeMaND2 project. The authors express their sincere gratitude to Professor Hans
456 Nauwynck (Laboratory of Virology, Faculty of Veterinary Medicine, Ghent University, Belgium) for
457 the generous gift of both ST cells and PRCV strain 91V44. Within the framework of the Infection

458 Prevention and Control (IPC) and World Health Emergencies (WHE) programmes of the World
459 Health Organisation (WHO), we are grateful to Leandro Pecchia, Madison Moon, Brian Adams, Lisa
460 Umphrey, Benedetta Allegranzi, and April Baller for their administrative advice and guidance
461 throughout this project.

462

463 CONFLICTS OF INTEREST STATEMENT

464 T.S.L. is a cofounder of Singletto, Inc. All other authors report no conflicts of interest relevant to this
465 article. The findings and conclusions in this report are those of the authors and do not necessarily
466 represent the views of the Centers for Disease Control and Prevention or the US Department of Health
467 and Human Services.

468

469 FUNDING SOURCE

470 This work was supported by a grant from the Walloon Region, Belgium (project 2010053 -2020-
471 “MASK - Decontamination and reuse of surgical masks and filtering facepiece respirators”), two
472 ULiège Fonds Spéciaux pour la Recherche grants (FSR Crédits Classiques – 2020 and Crédits
473 Sectoriels de Recherche en Sciences de la Santé – 2021), and by German Federal Ministry of Health
474 (BMG) COVID-19 Research and development funding to the WHO.

475

476 REFERENCES

477

- 478 [1] Strasser BJ, Schlich T. A history of the medical mask and the rise of throwaway culture. *Lancet*
479 2020;396:19–20. [https://doi.org/10.1016/S0140-6736\(20\)31207-1](https://doi.org/10.1016/S0140-6736(20)31207-1).
- 480 [2] Ibn-Mohammed T, Mustapha KB, Godsell J, Adamu Z, Babatunde KA, Akintade DD, et al. A
481 critical review of the impacts of COVID-19 on the global economy and ecosystems and
482 opportunities for circular economy strategies. *Resour Conserv Recycl* 2021;164:105169.
483 <https://doi.org/10.1016/j.resconrec.2020.105169>.
- 484 [3] World Health Organization (WHO). Rational use of personal protective equipment for
485 coronavirus disease 2019 (COVID-19). *Who* 2020;2019:1–7.

- 486 [4] Implementing Filtering Facepiece Respirator (FFR) Reuse, Including Reuse after
487 Decontamination, When There Are Known Shortages of N95 Respirators. Centers Dis Control
488 Prev 2020. [https://www.cdc.gov/coronavirus/2019-ncov/hcp/ppe-strategy/decontamination-](https://www.cdc.gov/coronavirus/2019-ncov/hcp/ppe-strategy/decontamination-reuse-respirators.html)
489 [reuse-respirators.html](https://www.cdc.gov/coronavirus/2019-ncov/hcp/ppe-strategy/decontamination-reuse-respirators.html) (accessed October 6, 2020).
- 490 [5] Center for Devices and Radiological Health. Enforcement Policy for Face Masks and
491 Respirators During the Coronavirus Disease (COVID-19) Public Health Emergency (Revised)
492 Guidance for Industry and Food and Drug Administration Staff 2020.
- 493 [6] Croke L. Preparing for the next infectious disease pandemic. *AORN J* 2020;112:P12–4.
494 <https://doi.org/10.1002/aorn.13188>.
- 495 [7] Kramer A, Schwebke I, Kampf G. How long do nosocomial pathogens persist on inanimate
496 surfaces? A systematic review. *BMC Infect Dis* 2006;6:1–8. [https://doi.org/10.1186/1471-](https://doi.org/10.1186/1471-2334-6-130)
497 [2334-6-130](https://doi.org/10.1186/1471-2334-6-130).
- 498 [8] Robilotti E, Deresinski S, Pinsky BA. Norovirus. *Clin Microbiol Rev* 2015;28:134–64.
499 <https://doi.org/10.1128/CMR.00075-14>.
- 500 [9] Zonta W, Mauroy A, Farnir F, Thiry E. Comparative Virucidal Efficacy of Seven Disinfectants
501 Against Murine Norovirus and Feline Calicivirus, Surrogates of Human Norovirus. *Food*
502 *Environ Virol* 2015. <https://doi.org/10.1007/s12560-015-9216-2>.
- 503 [10] Ludwig-Begall LF, Mauroy A, Thiry E. Noroviruses—The State of the Art, Nearly Fifty Years
504 after Their Initial Discovery. *Viruses* 2021;13:1541.
- 505 [11] Nims RW, Zhou SS. Intra-family differences in efficacy of inactivation of small, non-
506 enveloped viruses. *Biologicals* 2016;44:456–62.
507 <https://doi.org/10.1016/j.biologicals.2016.05.005>.
- 508 [12] Ludwig-Begall LF, Wielick C, Dams L, Nauwynck H, Demeuldre P-F, Napp A, et al. The use
509 of germicidal ultraviolet light, vaporised hydrogen peroxide and dry heat to decontaminate face
510 masks and filtering respirators contaminated with a SARS-CoV-2 surrogate virus. *J Hosp*
511 *Infect* 2020. <https://doi.org/10.1016/j.jhin.2020.08.025>.
- 512 [13] Wielick C, Ludwig-Begall LF, Dams L, Razafimahefa RM, Demeuldre P-F, Napp A, et al. The
513 use of germicidal ultraviolet light, vaporised hydrogen peroxide and dry heat to decontaminate

- 514 face masks and filtering respirators contaminated with an infectious norovirus. *Infect Prev*
515 *Pract* 2020;3:100111. <https://doi.org/10.1016/j.infpip.2020.100111>.
- 516 [14] Ludwig-Begall LF, Wielick C, Jolois O, Dams L, Razafimahefa RM, Nauwynck H, et al. “Don,
517 doff, discard” to “don, doff, decontaminate” – FFR and mask integrity and inactivation of a
518 SARS-CoV-2 surrogate and a norovirus following multiple vaporised hydrogen peroxide-,
519 ultraviolet germicidal irradiation-, and dry heat decontaminations. *PLoS One* 2021.
- 520 [15] Lendvay TS, Chen J, Harcourt BH, Scholte FEM, Lin YL, Kilinc-Balci FS, et al. Addressing
521 personal protective equipment (PPE) decontamination: Methylene blue and light inactivates
522 SARS-COV-2 on N95 respirators and medical masks with maintenance of integrity and fit.
523 *Infect Control Hosp Epidemiol* 2021;2019:1–10. <https://doi.org/10.1017/ice.2021.230>.
- 524 [16] Costa L, Faustino MAF, Neves MGPMS, Cunha Â, Almeida A. Photodynamic inactivation of
525 mammalian viruses and bacteriophages. *Viruses* 2012;4:1034–74.
526 <https://doi.org/10.3390/v4071034>.
- 527 [17] Eickmann M, Gravemann U, Handke W, Tolksdorf F, Reichenberg S, Müller TH, et al.
528 Inactivation of Ebola virus and Middle East respiratory syndrome coronavirus in platelet
529 concentrates and plasma by ultraviolet C light and methylene blue plus visible light,
530 respectively. *Transfusion* 2018;58:2202–7. <https://doi.org/10.1111/trf.14652>.
- 531 [18] Seghatchian J, Walker WH, Reichenberg S. Updates on pathogen inactivation of plasma using
532 Theraflex methylene blue system. *Transfus Apher Sci* 2008;38:271–80.
533 <https://doi.org/10.1016/j.transci.2008.04.004>.
- 534 [19] Genina EA, Bashkatov AN, Chikina EE, Knyazev AB, Mareev O V., Tuchin V V. Methylene
535 blue mediated laser therapy of maxillary sinusitis. *Laser Phys* 2006;16:1128–33.
536 <https://doi.org/10.1134/s1054660x06070188>.
- 537 [20] McClurkin AW, Norman JO. Studies on transmissible gastroenteritis of swine. II. Selected
538 characteristics of a cytopathogenic virus common to five isolates from transmissible
539 gastroenteritis. *Can J Comp Med Vet Sci* 1966;30:190–8.
- 540 [21] Cox E, Hooyberghs J, Pensaert MB. Sites of replication of a porcine respiratory coronavirus
541 related to transmissible gastroenteritis virus. *Res Vet Sci* 1990;48:165–169.

- 542 [22] Reed, L.J.; Muench H. A simple method of estimating fifty percent endpoints. *Am J Hyg*
543 1938;27.
- 544 [23] Lendvay TS, Chen J, Harcourt BH, Scholte FEM, Kilinc-Balci FS, Lin YL, et al. Addressing
545 Personal Protective Equipment (PPE) Decontamination□: Methylene Blue and Light
546 Inactivates SARS-CoV-2 on N95 Respirators and Masks with Maintenance of Integrity and Fit.
547 *MedRxiv* 2020.
- 548 [24] Kingsley D, Kuis R, Perez R, Basaldua I, Burkins P, Marcano A, et al. Oxygen-dependent laser
549 inactivation of murine norovirus using visible light lasers. *Virology* 2018;15:1–8.
550 <https://doi.org/10.1186/s12985-018-1019-2>.
- 551 [25] Fondriest Environmental Inc. Dissolved Oxygen - Fundamentals of Environmental
552 Measurements 2013. [https://www.fondriest.com/environmental-](https://www.fondriest.com/environmental-measurements/parameters/water-quality/dissolved-oxygen)
553 [measurements/parameters/water-quality/dissolved-oxygen](https://www.fondriest.com/environmental-measurements/parameters/water-quality/dissolved-oxygen).
- 554 [26] Seghatchian J, Struff WG, Reichenberg S. Main properties of the THERAFLEX MB-plasma
555 system for pathogen reduction. *Transfus Med Hemotherapy* 2011;38:55–64.
556 <https://doi.org/10.1159/000323786>.
- 557 [27] Rengelshausen J, Burhenne J, Fröhlich M, Tayrouz Y, Singh SK, Riedel KD, et al.
558 Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria.
559 *Eur J Clin Pharmacol* 2004;60:709–15. <https://doi.org/10.1007/s00228-004-0818-0>.